ReadoutOct 19, 2026
Clinical data — Reported Sunday, Lilly Brings Updated Phase 3 Selpercatinib Data Versus Cabozantinib Or Vandetanib In RET-Mutant Medull…▸
medium impact
ReadoutOct 18, 2026
Clinical data — Lilly to showcase advances across its oncology pipeline at the 2026 European Society for Medical Oncology (ESMO) Congre…▸
medium impact
FilingOct 16, 2026
Regulatory filing — Eli Lilly Receives EMA CHMP Positive Opinion Recommending Marketing Authorization For Foundayo For Treatment Of Type 2…▸
medium impact
AdComOct 16, 2026
FDA advisory — Lilly’s Foundayo Pill Gets European Regulatory Backing – LLY Stock Heads For Best Week In Nearly Four Months▸
high impact
FailureOct 12, 2026
Discontinuation — This Drug Combination for Eli Lilly Generated Significantly More Weight Loss Than Just Zepbound, but Discontinuation Ra…▸
high impact
ReadoutOct 12, 2026
Clinical data — Eli Lilly (LLY) Phase 3b Win Connects Psoriasis And Obesity Treatment▸
medium impact
DealOct 08, 2026
Deal — Is InnoCare Pharma (SEHK:9969) Undervalued On Its Eli Lilly Deal?▸
medium impact
EarningsAug 05, 2026
Q2 2026 report+5.3%positive
EarningsApr 30, 2026
Q1 2026 report+5.8%positive
EarningsFeb 04, 2026
FY 2025 report-5.6%negative
EarningsOct 30, 2025
Q3 2025 report+7.4%positive
EarningsAug 07, 2025
Q2 2025 report-0.2%muted
EarningsMay 01, 2025
Q1 2025 report-2.4%muted
EarningsFeb 06, 2025
FY 2024 report-0.6%muted
EarningsJan 14, 2025
FY 2024 report-2.6%muted
EarningsOct 30, 2024
Q3 2024 report-4.8%negative